- Home
- VRNS vs PCVX Comparison
VRNS vs PCVX Comparison
Compare VRNS & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRNS
- PCVX
- Stock Information
- Founded
- VRNS 2004
- PCVX 2013
- Country
- VRNS United States
- PCVX United States
- Employees
- VRNS N/A
- PCVX N/A
- Industry
- VRNS Computer Software: Prepackaged Software
- PCVX Biotechnology: Pharmaceutical Preparations
- Sector
- VRNS Technology
- PCVX Health Care
- Exchange
- VRNS Nasdaq
- PCVX Nasdaq
- Market Cap
- VRNS 4.4B
- PCVX 4.4B
- IPO Year
- VRNS 2014
- PCVX 2020
- Fundamental
- Price
- VRNS $59.11
- PCVX $32.29
- Analyst Decision
- VRNS Buy
- PCVX Strong Buy
- Analyst Count
- VRNS 16
- PCVX 10
- Target Price
- VRNS $60.31
- PCVX $136.50
- AVG Volume (30 Days)
- VRNS 1.7M
- PCVX 1.3M
- Earning Date
- VRNS 07-29-2025
- PCVX 08-06-2025
- Dividend Yield
- VRNS N/A
- PCVX N/A
- EPS Growth
- VRNS N/A
- PCVX N/A
- EPS
- VRNS N/A
- PCVX N/A
- Revenue
- VRNS $595,168,000.00
- PCVX N/A
- Revenue This Year
- VRNS $14.92
- PCVX N/A
- Revenue Next Year
- VRNS $16.53
- PCVX N/A
- P/E Ratio
- VRNS N/A
- PCVX N/A
- Revenue Growth
- VRNS 14.29
- PCVX N/A
- 52 Week Low
- VRNS $36.53
- PCVX $27.66
- 52 Week High
- VRNS $60.58
- PCVX $121.06
- Technical
- Relative Strength Index (RSI)
- VRNS 65.02
- PCVX 47.44
- Support Level
- VRNS $57.13
- PCVX $30.69
- Resistance Level
- VRNS $58.88
- PCVX $33.14
- Average True Range (ATR)
- VRNS 1.62
- PCVX 1.26
- MACD
- VRNS 0.14
- PCVX 0.10
- Stochastic Oscillator
- VRNS 93.36
- PCVX 59.23
About VRNS Varonis Systems Inc.
Varonis Systems is a cybersecurity vendor focused on data privacy and security. The firm is currently undergoing a cloud transition as it weans its on-premises customers over to its cloud products that are delivered as software-as-a-service. The New York-based firm was founded in 2005 and went public in 2014.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.